KR870010871A - 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 - Google Patents

재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 Download PDF

Info

Publication number
KR870010871A
KR870010871A KR870005198A KR870005198A KR870010871A KR 870010871 A KR870010871 A KR 870010871A KR 870005198 A KR870005198 A KR 870005198A KR 870005198 A KR870005198 A KR 870005198A KR 870010871 A KR870010871 A KR 870010871A
Authority
KR
South Korea
Prior art keywords
alpha
interferon
cell carcinoma
basal cell
recombinant human
Prior art date
Application number
KR870005198A
Other languages
English (en)
Inventor
제이 탄너 다니엘
아놀드 피츠 에드윈
알버트 스마일즈 켄네스
Original Assignee
에릭 에스 딕커
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에릭 에스 딕커, 쉐링 코포레이션 filed Critical 에릭 에스 딕커
Publication of KR870010871A publication Critical patent/KR870010871A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 기저세포(basal cell) 암종 치료제로서 효과적인 충분한 양의 인체알파 (alpha) 인터페론을 기저세포 암종 환자에게 병소내적으로 투여하여 인체의 기저세포 암종을 치료하는 방법.
  2. 제 1항에 있어서, 알파(alpha) 인터페론이 알파-2(alpha-2) 인터페론인 방법.
  3. 제 2항에 있어서, 알파-2(alpha-2) 인터페론이 재조합 인체 인터페론 알파-2(alfa-2)인 방법.
  4. 제 3항에 있어서, 재조합 인체 인터페론이 알파-2b(alfa-2b)인 방법.
  5. 기저세포 암종에 대해 효과적인 충분한 양의 인체 알파(alpha) 인터페론 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물 제제에서의 인체알파(alpha) 인터페론의 인체 기저세포 암종을 치료하기 위한 용도.
  6. 제 5항에 있어서, 알파(alpha) 인터페론이 알파-2(alpha-2) 인터페론인 용도.
  7. 제 6항에 있어서, 알파-2(alpha-2) 인터페론이 재조합 인체 인터페론 알파-2(alfa-2)인 용도.
  8. 제 7항에 있어서, 재조합 인체 인터페론이 알파-2b(alfa-2b)인 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870005198A 1986-05-27 1987-05-26 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 KR870010871A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86664486A 1986-05-27 1986-05-27
US866644 1986-05-27

Publications (1)

Publication Number Publication Date
KR870010871A true KR870010871A (ko) 1987-12-18

Family

ID=25348060

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870005198A KR870010871A (ko) 1986-05-27 1987-05-26 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법

Country Status (13)

Country Link
EP (1) EP0248583B1 (ko)
JP (1) JPS62289526A (ko)
KR (1) KR870010871A (ko)
AT (1) ATE100717T1 (ko)
AU (1) AU601741B2 (ko)
CA (1) CA1295243C (ko)
DE (1) DE3788899T2 (ko)
DK (1) DK264787A (ko)
ES (1) ES2061496T3 (ko)
IE (1) IE62318B1 (ko)
IL (1) IL82654A0 (ko)
PH (1) PH26198A (ko)
ZA (1) ZA873743B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
EP0278715A3 (en) * 1987-02-09 1989-03-08 Schering Corporation Use of human gamma interferon for treatment of basal cell carcinoma
US5256410A (en) * 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
ATE92333T1 (de) * 1988-12-01 1993-08-15 Schering Corp Arzneimittel zur intralesionsbehandlung von schuppenartigem zellkarzinomen mit rekombinantem human-alpha-interferon.
IL100415A0 (en) * 1990-12-21 1992-09-06 Schering Corp Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
US20200038487A1 (en) * 2017-03-31 2020-02-06 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (nmsc)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305551A3 (en) * 1981-10-13 1990-01-10 Exovir, Inc. Pharmaceutical compositions for topical application
WO1983002460A1 (en) * 1982-01-15 1983-07-21 Cetus Corp Interferon-alpha 74
US5098703A (en) * 1982-01-15 1992-03-24 Cetus Corporation Interferon-alpha 76
AU1153083A (en) * 1982-01-15 1983-07-28 Cetus Corporation Interferon-alpha 54
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex

Also Published As

Publication number Publication date
DK264787D0 (da) 1987-05-25
ZA873743B (en) 1987-11-25
EP0248583A2 (en) 1987-12-09
EP0248583B1 (en) 1994-01-26
AU7336687A (en) 1987-12-03
CA1295243C (en) 1992-02-04
IE871358L (en) 1987-11-27
DE3788899D1 (de) 1994-03-10
PH26198A (en) 1992-03-18
IL82654A0 (en) 1987-11-30
DE3788899T2 (de) 1994-05-05
JPS62289526A (ja) 1987-12-16
EP0248583A3 (en) 1989-10-18
ES2061496T3 (es) 1994-12-16
AU601741B2 (en) 1990-09-20
IE62318B1 (en) 1995-01-25
DK264787A (da) 1987-11-28
ATE100717T1 (de) 1994-02-15

Similar Documents

Publication Publication Date Title
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
EP0317568A4 (en) Use of stimulation of granulocyte-macrophage colonies for obtaining a medicament for the treatment of bacterial diseases.
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR910005858A (ko) 지방산 요법
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
ZA90600B (en) Treatment of leukocyte dysefunction with gm-csf
ATE94763T1 (de) Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung.
KR900701309A (ko) 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
KR880004810A (ko) 소화성 궤양 치료제
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
SE8804640L (sv) Laekemedel omfattande cyklolinopeptide a
KR900017599A (ko) 종양 치료용 약학 조성물
KR880000094A (ko) 위염치료제
KR870005642A (ko) 디플루니살과 트로메타민의 혼합물
Richtsmeier The interferons
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
IT1236834B (it) Complessi del 4-idrossi-2-metil-n--2-piridinil-2-h,2-benzotiazina-3- carbossiammide-1,1-diossido con cilodestrine, aventi azione anti- infiammatoria, procedimento per la loro preparazione e relative composizioni farmaceutiche.
SE8903117D0 (sv) Laekemedel omfattande antamanid
KR890001549A (ko) 위염 치료제
KR880001300A (ko) 리트로바이러스 감염의 예방 및 치료를 위한 방법 및 조성물
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
HU900202D0 (en) Process for manufacturing of pharmaceutical compositions comprising gamma-interferon suitable to treatment of ovarion cancer

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application